Study to Evaluate the Efficacy and Safety of BBP-418 (Ribitol) in Patients With Limb Girdle Muscular Dystrophy 2I (LGMD2I)

Running, not enrolling · Phase 3 · Has a placebo group

Conditions studied: Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I)

In brief

This study will evaluate the safety and efficacy of long-term administration of BBP-418 in patients with LGMD2I/R9. The study will include patients ages 12 to 60, consistent with the existing preclinical toxicology profile. This will encompass the significant majority of existing diagnosed patients based upon the established epidemiology of the disease.

Key facts

Study ID
NCT05775848
Run by
ML Bio Solutions, Inc.
People needed
81
Starts
2023-05-31
Expected to finish
2027-07-01
Last updated by the study team
2025-09-29

Who can join

Age: 12 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.